Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBITDA: 2018-2024

Historic EBITDA for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$256.7 million.

  • Allogene Therapeutics' EBITDA rose 37.08% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.9 million, marking a year-over-year increase of 24.54%. This contributed to the annual value of -$256.7 million for FY2024, which is 19.34% up from last year.
  • Per Allogene Therapeutics' latest filing, its EBITDA stood at -$256.7 million for FY2024, which was up 19.34% from -$318.3 million recorded in FY2023.
  • Allogene Therapeutics' EBITDA's 5-year high stood at -$184.9 million during FY2021, with a 5-year trough of -$347.8 million in FY2022.
  • Its 3-year average for EBITDA is -$307.6 million, with a median of -$318.3 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 41.72% in 2021, then plummeted by 88.10% in 2022.
  • Yearly analysis of 5 years shows Allogene Therapeutics' EBITDA stood at -$317.3 million in 2020, then spiked by 41.72% to -$184.9 million in 2021, then slumped by 88.10% to -$347.8 million in 2022, then rose by 8.48% to -$318.3 million in 2023, then rose by 19.34% to -$256.7 million in 2024.